Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072116 | 0.97 | CA12 (0.46) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL7072150 | 0.94 | PDK2 (0.47) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL7073260 | 0.87 | GAA (0.43) | CACNA1GHDAC2HDAC8HDAC6 | |
| SCHEMBL7078644 | 0.85 | GAA (0.43) | CACNA1GHDAC2HDAC8HDAC6 | |
| SCHEMBL7075422 | 0.83 | CACNA1G (0.38) | CA12CA1CA2CA9CACNA1G | |
| SCHEMBL7073177 | 0.83 | DGAT1 (0.41) | CACNA1GHDAC2HDAC8HDAC6 | |
| Trifluoroacetic Acid SCHEMBL7073057 | 0.83 | DRD2 (0.36) | PDK2DRD2 | |
| SCHEMBL7079699 | 0.82 | DDB1 (0.38) | CA12CA1CA2CA9CACNA1G | |
| SCHEMBL7072126 | 0.82 | CA12 (0.46) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL7079103 | 0.81 | HTT (0.40) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | CA12 4002/4885CA1 2574/4885CA2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.